Menu Search
Equities

Obio Technology Shanghai Corp Ltd

688238:SHH

Obio Technology Shanghai Corp Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)4.05
  • Today's Change0.00 / 0.00%
  • Shares traded4.66m
  • 1 Year change-59.05%
  • Beta--
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Obio Technology Shanghai Corp Ltd's revenues fell -29.69% from 291.30m to 204.81m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a gain of 39.26m to a loss of 127.94m.
Gross margin-19.93%
Net profit margin-84.03%
Operating margin-91.28%
Return on assets-7.88%
Return on equity-9.65%
Return on investment-8.68%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Obio Technology Shanghai Corp Ltd fell by 557.59m. Cash Flow from Financing totalled 134.12m or 65.49% of revenues. In addition the company used 90.12m for operations while cash used for investing totalled 601.55m.
Cash flow per share--
Price/Cash flow per share--
Book value per share3.00
Tangible book value per share2.92
More ▼

Balance sheet in CNYView more

Obio Technology Shanghai Corp Ltd appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.26% of the market capitalization can be attributed to its 652.99m and debt could be paid in full if management chose.
Current ratio2.40
Quick ratio2.14
Total debt/total equity0.1271
Total debt/total capital0.1128
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.